Wedbush Weighs in on Chimerix’s Q4 Earnings (NASDAQ:CMRX)

Chimerix, Inc. (NASDAQ:CMRX) – Equities researchers at Wedbush cut their Q4 2025 earnings estimates for shares of Chimerix in a research note issued to investors on Tuesday, December 10th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post earnings of ($0.28) per share for the quarter, down from their previous estimate of $0.28. Wedbush currently has a “Outperform” rating and a $6.00 price objective on the stock. The consensus estimate for Chimerix’s current full-year earnings is ($0.99) per share. Wedbush also issued estimates for Chimerix’s FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.06) EPS and FY2028 earnings at $0.47 EPS.

A number of other analysts also recently commented on the company. StockNews.com upgraded Chimerix from a “sell” rating to a “hold” rating in a research report on Wednesday, August 21st. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Chimerix in a report on Wednesday.

Chimerix Price Performance

Shares of NASDAQ:CMRX opened at $2.94 on Friday. The business’s 50 day simple moving average is $1.03 and its 200-day simple moving average is $0.94. Chimerix has a 12 month low of $0.75 and a 12 month high of $3.39.

Institutional Investors Weigh In On Chimerix

A number of hedge funds and other institutional investors have recently made changes to their positions in CMRX. Valeo Financial Advisors LLC lifted its stake in shares of Chimerix by 566.9% in the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 69,505 shares in the last quarter. Marshall Wace LLP acquired a new position in Chimerix during the 2nd quarter worth $137,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after purchasing an additional 138,098 shares during the last quarter. Hedge funds and other institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.